Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.
Prevalence and factors associated with non-adherence to multi-drug resistant tuberculosis (MDR-TB) treatment at Mulago National Referral Hospital, Kampala, Uganda.
复制标题
乌干达坎帕拉Mulago国家转诊医院耐多药结核病（MDR-TB）治疗不依从性的患病率和相关因素。
DOI：
10.4314/ahs.v21i1.31
复制
发表时间：
2021-03
影响因子：
1
通讯作者：
Katamba A
中科院分区：
文献类型：
--
作者：
Batte C;Namusobya MS;Kirabo R;Mukisa J;Adakun S;Katamba A
In Uganda, 12% of previously treated TB cases and 1.6% of new cases have MDR-TB and require specialized treatment and care. Adherence is crucial for improving MDR-TB treatment outcomes. There is paucity of information on the extent to which these patients adhere to treatment and what the drivers of non-adherence are. We conducted a cohort study using retrospectively collected routine program data for patients treated for MDR-TB between January 2012 – May 2016 at Mulago Hospital. We extracted anonymized data on non-adherence (missing 10% or more of DOT), socio-economic, demographic, and treatment characteristics of the patients. All participants were sensitive to MDR-TB drugs after second line Drug Susceptible Testing (DST) at entry into the study. Factors associated with non-adherence to MDR-TB treatment were determined using generalized linear models for the binomial family with log link and robust standard errors. We considered a p- value less than 0.05 as statistically significant. The records of 227 MDR- TB patients met the inclusion criteria, 39.4% of whom were female, 32.6% aged between 25 – 34 years, and 54.6% living with HIV/AIDS. About 11.9% of the patients were non-adherent. The main driver for non-adherence was history of previous DR-TB treatment; previously treated DR-TB patients were 3.46 (Adjusted prevalence ratio: 3.46, 95 % CI: 1.68 – 7.14) times more likely to be non-adherent. One in 10 MDR-TB patients treated at Mulago hospital is non-adherent to treatment. History of previous DRTB treatment was significantly associated with non-adherence in this study. MDR-TB program should strengthen adherence counselling, strengthen DST surveillance, and close monitoring for previously treated DR-TB patients.
登录
查看更多内容
影响因子：
3.7
作者：
Modongo C;Sobota RS;Kesenogile B;Ncube R;Sirugo G;Williams SM;Zetola NM
通讯作者：
Zetola NM
在乌干达坎帕拉住院的新结核病患者的治疗结果：一项前瞻性队列研究。
影响因子：
3.7
作者：
Kirenga BJ;Levin J;Ayakaka I;Worodria W;Reilly N;Mumbowa F;Nabanjja H;Nyakoojo G;Fennelly K;Nakubulwa S;Joloba M;Okwera A;Eisenach KD;McNerney R;Elliott AM;Mugerwa RD;Smith PG;Ellner JJ;Jones-López EC
通讯作者：
Jones-López EC
影响因子：
1.8
作者：
Mekonnen HS;Azagew AW
通讯作者：
Azagew AW
影响因子：
3.7
作者：
Lukoye, Deus;Adatu, Francis;Joloba, Moses L.
通讯作者：
Joloba, Moses L.
影响因子：
11.8
作者：
Peloquin, CA;Berning, SE;Curran-Everett, D
通讯作者：
Curran-Everett, D